Med. praxi. 2021;18(1):63-67 | DOI: 10.36290/med.2021.010

What a general practitioner should know about bronchogenic carcinoma

MUDr. Jaromír Roubec, Ph.D.
Komplexní onkologické centrum Nový Jičín

The review provides essential information on the epidemiology, diagnosis, and treatment of bronchogenic carcinoma in accordance with standard procedures in the Czech Republic, utilizing all treatment modalities based on histology and disease extent according to the stages of TNM classification. Using additional results of laboratory diagnostic procedures, the article discusses options of treatment with biological agents and personalization of treatment of this serious disease in line with current knowledge.

Keywords: bronchogenic carcinoma, diagnosis, treatment.

Published: April 6, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Roubec J. What a general practitioner should know about bronchogenic carcinoma. Med. praxi. 2021;18(1):63-67. doi: 10.36290/med.2021.010.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. www.svod.cz
    2. Ryska A, Berzinec P, Brcic L, et al. NSCLC molecular testing in Central and Eastern European countries. BMC Cancer. 2018; 18(1): 269. doi: 10.1186/s12885-018-4023-4. Go to original source... Go to PubMed...
    3. Jackman DM, Johnson BE. Small-cell lung cancer. Lancet. 2005; 366(9494): 1385-1396. Go to original source... Go to PubMed...
    4. TNM Klasifikace zhoubných novotvarů, 8. vydání (originál 2017). www.uzis.cz.
    5. Laskin JJ, Sander AB. State of the Art in Therapy for Non-Small Cell Lung Cancer. Cancer Investigation, 2005; 23: 427-442. Go to original source... Go to PubMed...
    6. Modrá kniha České onkologické společnosti, 2019. Dostupné z: http://www.linkos.cz/informace-pro-praxi/modra-kniha/
    7. Feigenberg SJ, Hanlon AL, Langer C, et al. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer. J Thorac Oncol. 2007; 2(4): 287-292. Go to original source... Go to PubMed...
    8. Domont J, Soria JCh, Le Chevalier T. Adjuvant Chemotherapy in Early -Stage Non-Small Cell Lung Cancer. Semin Oncol 2005; 32: 279-283. Go to original source... Go to PubMed...
    9. Scaglioti G, Brodowicz T, Shepherd FA, et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol. 2011; 6(1): 64-70. Go to original source... Go to PubMed...
    10. Reck M, von Pawel J, Zatloukal P, et al. Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL. J Clin Oncol. 2009; 28: 1227-1234. Go to original source... Go to PubMed...
    11. Cohen S, Levi-Montalcini R. Purification and properties of a nerve growth-promoting factor isolated from mouse sarcoma 180. Cancer Res. 1957; 17(1): 15-20.
    12. Goss G, Tsai CM, Shepherd FA, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study Lancet Oncol. 2016; 17(12): 1643-1652. Go to original source... Go to PubMed...
    13. Sun X, Roudi R, Dai T, et al. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. BMC Cancer. 2019; 19(1): 558. doi: 10.1186/s12885-019-5701-6. Go to original source... Go to PubMed...
    14. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatement of metastatic nonsquamous NSCLC. N Engl J Med 2018; 378: 2288-2301. Go to original source... Go to PubMed...
    15. West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019; 20(7): 924-937. Go to original source... Go to PubMed...
    16. Spigel D, de Marinis F, Giaccone G, et al. IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC. Ann Oncol 2019; 30(Suppl. 5): v851-934. Go to original source...
    17. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017; 377(20): 1919-1929. Go to original source... Go to PubMed...
    18. Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019; 381(21): 2020-2031. Go to original source... Go to PubMed...
    19. Press release: https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-withdraws-european-application-opdivo-niv.
    20. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373(17): 1627-1639. Go to original source... Go to PubMed...
    21. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-135. Go to original source... Go to PubMed...
    22. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387(10027): 1540-1550. Go to original source... Go to PubMed...
    23. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small cell lung cancer. N Engl J Med 2016; 375(19): 1823-1833. Go to original source... Go to PubMed...
    24. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50 % or greater. J Clin Oncol 2019; 37(7): 537-546. Go to original source... Go to PubMed...
    25. Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small cell lung cancer. N Engl J Med 2018; 378(22): 2078-2092. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.